Skip to main content
Premium Trial:

Request an Annual Quote

Tekmira Starts Phase I Study of Ebola Treatment

Premium

Tekmira Pharmaceuticals said this week that it has begun enrolling patients in a phase I trial of its Ebola virus infection treatment TKM-Ebola.

The 56-patient, placebo-controlled study has two arms. The first will test single ascending doses of the siRNA-based drug in up to six cohorts of four patients each. The second arm will examine multiple ascending doses in three four-patient cohorts.

TKM-Ebola is being developed with the support of a $140 million contract from the US government. In 2010, Tekmira showed that a cocktail of modified siRNAs targeting the Zaire Ebola virus L polymerase, viral protein 24, and viral protein 35 could completely protect non-human primates from a lethal dose of the virus when delivered using proprietary lipid nanoparticles (GSN 8/9/2010).

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.